SCHEMBL5879259

SCHEMBL5879259

Cc1ccc2[nH]cc(C3=CC(=O)NC3=O)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SLC6A4 P31645 2/20 0.43
IDO1 P14902 1/20 0.43
PDGFRB P09619 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 2/20 0.41
RAB9A P51151 1/20 0.41
NR4A2 P43354 1/20 0.41
HTR1A P08908 1/20 0.41
HTR7 P34969 1/20 0.41
PRKCB P05771 3/20 0.41
HTR1D P28221 1/20 0.40
HTR2A P28223 1/20 0.40
PRKD3 O94806 1/20 0.40
CCNB2 O95067 1/20 0.40
CCNE2 O96020 1/20 0.40
ABL1 P00519 1/20 0.40
PRKCG P05129 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879200 0.88 CDK4 (0.46) KDM4EHSD17B10IDO1MEN1KMT2A
SCHEMBL5879171 0.82 CLK1 (0.45) PDGFRBPRKCBHTR1DPRKD3CCNB2
SCHEMBL5879255 0.82 IGF1R (0.50) KDM4ESLC6A4IDO1PDGFRBHTR1A
SCHEMBL5879252 0.82 PDGFRB (0.50) SLC6A4IDO1PDGFRBNR4A2HTR1A
SCHEMBL5879170 0.82 F7 (0.45) SLC6A4IDO1MEN1KMT2ANR4A2
SCHEMBL5879151 0.82 BRAF (0.44) PDGFRBLMNAHTR1AHTR7PRKCB
SCHEMBL10433699 0.82 HTR3E (0.42) KDM4EHSD17B10PDGFRBHTR1AHTR7
SCHEMBL10433674 0.82 JAK2 (0.46) KDM4EHSD17B10PDGFRBPRKCBPRKD3
SCHEMBL5879148 0.82 KDR (0.57) KDM4EHSD17B10SLC6A4IDO1PDGFRB
SCHEMBL7815050 0.81 PRKCB (0.60) KDM4EHSD17B10SLC6A4IDO1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed
EP-0397060-A2 Maleinimide derivatives and their use as medicines GÖDECKE AKTIENGESELLSCHAFT (DE) 1990-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 KDM4E 3154/4885HSD17B10 699/4885SLC6A4 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.